Targeting Bcl-2 family proteins modulates the sensitivity of B-cell lymphoma to rituximab-induced apoptosis

Claudia Stolz(Essen University Hospital), Martin Schüler(German Cancer Research Center)

Blood

August 9, 2008

10.1182/blood-2007-11-124487

Cited by 91

Related Papers

Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations

|Journal of Clinical Oncology|2013|3.2k

Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation

|New England Journal of Medicine|2021|1.8k

Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations

|New England Journal of Medicine|2015|1.7k

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

|The Lancet Oncology|2015|1.6k

Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6

|The Lancet Oncology|2015|980